TNF and hypohidrotic ectodermal dysplasia: In our study, logistic regression analysis of the examined parameters showed that higher baseline expression of TNF was associated with an increased likelihood of developing EDA and a greater risk of disability progression over a 2-year follow-up in patients with both RRMS and PPMS treated with ocrelizumab.